Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer
September 27 2021 - 8:00AM
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical
company developing a broad portfolio of product candidates
engineered to cross the blood-brain barrier (BBB) for
neurodegenerative diseases, today announced the appointment of
Katie Peng to the newly created role of Chief Commercial
Officer.
“We are excited about Katie joining Denali to build and lead our
commercial organization. She is a recognized industry leader with
an exceptional track record of successfully building and leading
commercial teams and launching novel medicines, including for
neurological and rare diseases,” said Denali’s Chief Executive
Officer, Ryan Watts, Ph.D. “Katie’s expertise will be tremendously
valuable to Denali as we advance our clinical pipeline, including
programs for Parkinson’s disease and Hunter syndrome (MPS II) into
late-stage clinical development. Katie’s leadership in building our
commercial efforts as we expand organizationally and geographically
will be key to bringing medicines to people living with
neurodegenerative diseases and our ultimate goal to defeat
degeneration.”
Ms. Peng most recently served as the Senior Vice President, Head
of the OMNI Business Unit at Genentech where she was responsible
for the neurology, ophthalmology, immunology, respiratory, and rare
diseases portfolio representing approximately $14 billion in
revenue, and served as part of Genentech’s commercial leadership
team. In her nearly two decades at Genentech and Roche, Ms. Peng
held a number of senior leadership positions including General
Manager for Roche in the Asia Pacific region leading the country
organizations in Taiwan and Singapore. Ms. Peng has successfully
launched multiple products in neurology, oncology, and rare disease
notably including OCREVUS® (ocrelizumab), a therapeutic monoclonal
antibody approved for the treatment of multiple sclerosis, Evrysdi®
(risdiplam), a medicine used to treat spinal muscular atrophy (SMA)
in adults and children, and HEMLIBRA® (emicizumab-kxwh), a
bispecific antibody for the treatment of people with hemophilia A.
Her commercial experience spans marketing, sales, market access,
medical affairs and business planning.
“I am thrilled to join Denali’s leadership team and build the
commercial organization,” said Ms. Peng. “Neurodegenerative
diseases are one of the biggest unmet medical needs of our time
and, like in oncology two decades ago, we are at a time of
exceptional progress fueled by new genetic insights and
biomarker-informed development. Denali is at the vanguard of this
revolution, with a broad pipeline of product candidates with
significant promise, and I am excited to contribute to building out
critical functions within Denali to help bring life-saving
medicines to people with neurodegenerative diseases.”
Prior to Genentech, Ms. Peng held several commercial roles at
Amgen and began her career as a research scientist at Allergan. Ms.
Peng holds a BA from the University of California, Berkeley and an
MBA from the Kelley School of Business, Indiana University.
About Denali TherapeuticsDenali
Therapeutics is a biopharmaceutical company developing a broad
portfolio of product candidates engineered to cross the blood-brain
barrier (BBB) for neurodegenerative diseases. Denali pursues new
treatments by rigorously assessing genetically validated targets,
engineering delivery across the BBB and guiding development through
biomarkers that demonstrate target and pathway engagement. Denali
is based in South San Francisco. For additional information,
please visit www.denalitherapeutics.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements expressed or implied in this press
release include, but are not limited to, statements regarding
Denali's progress, business plans, business strategy, product
candidates, planned preclinical studies and clinical trials and
expected milestones; and statements made by Denali’s Chief
Executive Officer and Chief Commercial Officer. Actual results are
subject to risks and uncertainties and may differ materially from
those indicated by these forward-looking statements as a result of
these risks and uncertainties, including but not limited to, risks
related to: any and all risks to Denali’s business and operations
caused directly or indirectly by the evolving COVID-19 pandemic;
risk of the occurrence of any event, change or other circumstance
that could give rise to the termination of Denali’s collaboration
agreements; Denali’s early stages of clinical drug development;
Denali’s and its partners’ ability to complete the development and,
if approved, commercialization of its product candidates; Denali’s
reliance on third parties for the manufacture and supply of its
product candidates for clinical trials; Denali’s and it's partners'
ability to conduct or complete clinical trials on expected
timelines; the uncertainty that product candidates will receive
regulatory approval necessary to be commercialized; Denali’s
ability to continue to create a pipeline of product candidates or
develop commercially successful products; Denali’s ability to
obtain, maintain, or protect intellectual property rights related
to its product candidates; implementation of Denali’s strategic
plans for its business, product candidates and blood-brain barrier
platform technology; and other risks, including those described in
Denali’s most recent Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) on August 4, 2021,
Denali’s Annual Report on Form 10-K filed with the SEC on February
26, 2021, and Denali’s future reports to be filed with the SEC. The
forward-looking statements in this press release are based on
information available to Denali as of the date hereof. Denali
disclaims any obligation to update any forward-looking statements,
except as required by law.
Investor Relations Contact: |
Media Contacts: |
|
Laura Hansen, Ph.D.Vice
President, Investor Relations(650) 452-2747hansen@dnli.com |
Lizzie Hyland(646)
495-2706lizzie.hyland@fgh.comorMorgan Warners(202)
295-0124morgan.warners@fgh.com |
|
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024